These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype. Bousette N; D'Orleans-Juste P; Kiss RS; You Z; Genest J; Al-Ramli W; Qureshi ST; Gramolini A; Behm D; Ohlstein EH; Harrison SM; Douglas SA; Giaid A Circ Res; 2009 Sep; 105(7):686-95, 19 p following 695. PubMed ID: 19696412 [TBL] [Abstract][Full Text] [Related]
24. Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death. Oumouna-Benachour K; Hans CP; Suzuki Y; Naura A; Datta R; Belmadani S; Fallon K; Woods C; Boulares AH Circulation; 2007 May; 115(18):2442-50. PubMed ID: 17438151 [TBL] [Abstract][Full Text] [Related]
25. Angiotensin-(1-7) dose-dependently inhibits atherosclerotic lesion formation and enhances plaque stability by targeting vascular cells. Yang JM; Dong M; Meng X; Zhao YX; Yang XY; Liu XL; Hao PP; Li JJ; Wang XP; Zhang K; Gao F; Zhao XQ; Zhang MX; Zhang Y; Zhang C Arterioscler Thromb Vasc Biol; 2013 Aug; 33(8):1978-85. PubMed ID: 23723368 [TBL] [Abstract][Full Text] [Related]
26. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Schieffer B; Selle T; Hilfiker A; Hilfiker-Kleiner D; Grote K; Tietge UJ; Trautwein C; Luchtefeld M; Schmittkamp C; Heeneman S; Daemen MJ; Drexler H Circulation; 2004 Nov; 110(22):3493-500. PubMed ID: 15557373 [TBL] [Abstract][Full Text] [Related]
27. Deficiency of inducible NO synthase reduces advanced but not early atherosclerosis in apolipoprotein E-deficient mice. Miyoshi T; Li Y; Shih DM; Wang X; Laubach VE; Matsumoto AH; Helm GA; Lusis AJ; Shi W Life Sci; 2006 Jul; 79(6):525-31. PubMed ID: 16516241 [TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Deguchi JO; Aikawa E; Libby P; Vachon JR; Inada M; Krane SM; Whittaker P; Aikawa M Circulation; 2005 Oct; 112(17):2708-15. PubMed ID: 16230484 [TBL] [Abstract][Full Text] [Related]
30. Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice. Atkinson RD; Coenen KR; Plummer MR; Gruen ML; Hasty AH Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E284-90. PubMed ID: 18029445 [TBL] [Abstract][Full Text] [Related]
31. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Paul A; Ko KW; Li L; Yechoor V; McCrory MA; Szalai AJ; Chan L Circulation; 2004 Feb; 109(5):647-55. PubMed ID: 14744975 [TBL] [Abstract][Full Text] [Related]
32. Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Sukhova GK; Wang B; Libby P; Pan JH; Zhang Y; Grubb A; Fang K; Chapman HA; Shi GP Circ Res; 2005 Feb; 96(3):368-75. PubMed ID: 15653570 [TBL] [Abstract][Full Text] [Related]
34. Uremia-specific effects in the arterial media during development of uremic atherosclerosis in apolipoprotein E-deficient mice. Bro S; Borup R; Andersen CB; Moeller F; Olgaard K; Nielsen LB Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):570-5. PubMed ID: 16373611 [TBL] [Abstract][Full Text] [Related]
35. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Keul P; Tölle M; Lucke S; von Wnuck Lipinski K; Heusch G; Schuchardt M; van der Giet M; Levkau B Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):607-13. PubMed ID: 17158351 [TBL] [Abstract][Full Text] [Related]
36. Decreased levels of lipid peroxidation-induced DNA damage in the onset of atherogenesis in apolipoprotein E deficient mice. Godschalk RW; Albrecht C; Curfs DM; Schins RP; Bartsch H; van Schooten FJ; Nair J Mutat Res; 2007 Aug; 621(1-2):87-94. PubMed ID: 17418875 [TBL] [Abstract][Full Text] [Related]
37. Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques. Suganuma E; Babaev VR; Motojima M; Zuo Y; Ayabe N; Fogo AB; Ichikawa I; Linton MF; Fazio S; Kon V J Am Soc Nephrol; 2007 Aug; 18(8):2311-9. PubMed ID: 17634441 [TBL] [Abstract][Full Text] [Related]
38. Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis. Sanz-González SM; Barquín L; García-Cao I; Roque M; González JM; Fuster JJ; Castells MT; Flores JM; Serrano M; Andrés V Cardiovasc Res; 2007 Sep; 75(4):803-12. PubMed ID: 17570351 [TBL] [Abstract][Full Text] [Related]
39. Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. Krohn R; Raffetseder U; Bot I; Zernecke A; Shagdarsuren E; Liehn EA; van Santbrink PJ; Nelson PJ; Biessen EA; Mertens PR; Weber C Circulation; 2007 Oct; 116(16):1812-20. PubMed ID: 17893273 [TBL] [Abstract][Full Text] [Related]
40. Endogenous angiotensin II enhances atherogenesis in apoprotein E-deficient mice with renovascular hypertension through activation of vascular smooth muscle cells. Heo HJ; Yun MR; Jung KH; Lee JY; Park JY; Lee SJ; Bae SS; Lee WS; Kim CD Life Sci; 2007 Feb; 80(11):1057-63. PubMed ID: 17204292 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]